STAT+: At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
This is the web version of STAT\u2019s\u00a0special newslette<\/a>r from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter\u00a0here<\/a>.<\/em><\/p>\n We\u2019re going to get to today\u2019s new data in a minute, but first let\u2019s deal\u00a0with a less serious matter:\u00a0the marketing of pharmaceutical products via the food attendees need to consume at giant medical meetings.<\/p>\n Genentech has been a longtime leader on this front. At cancer meetings, the cookies the company hands out at its booths are almost as famous as its drugs. An innovation this year: Genentech s\u2019mores, with Genentech-branded marshmallows toasted with a blowtorch. Warning: These things are messy. Other innovations in booth food: Novartis had charcuterie (guys, you know preserved meat is carcinogenic, right?) and Eli Lilly had a salad bar. The lettuce did not have a Lilly logo.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n